Quantcast

Latest Neuroendocrine tumor Stories

2011-04-11 12:16:00

SILVER SPRING, Md., April 11, 2011 /PRNewswire-USNewswire/ -- Science, public health, and regulatory highlights for this week from the U.S. Food and Drug Administration. Information in this document is designed for credentialed journalists. Release dates and times for items are current as of April 11, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) FDA News & Notes does not contain any regulatory or enforcement actions due to legal limitations. Meetings, Workshops...

2011-03-28 10:00:00

Preliminary analysis shows treatment is well-tolerated and consistently delivered to patients with metastatic liver cancer OTTAWA, March 28 /PRNewswire-FirstCall/ - Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today shared results from the first multi-site, Phase II clinical trial to evaluate TheraSphere® for treatment of metastatic liver cancer. The trial evaluated a variety of factors,...

2011-02-10 01:13:50

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers from The University of Texas MD Anderson Cancer Center. The findings were published in the latest New England Journal of Medicine. James C. Yao, M.D., associate professor in MD Anderson's Department of Gastrointestinal Medical...

2011-02-09 16:10:00

EAST HANOVER, N.J., Feb. 9, 2011 /PRNewswire/ -- The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)(1). Data from the study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), were first presented last year at...

2011-01-22 09:28:46

Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors. The work, described online in the Jan. 20 issue of Science Express, shows that patients whose tumors have certain coding "mistakes" live twice as long as those without them. "One of the most significant things we learned is that each patient with this kind of rare cancer has a unique genetic code that predicts how aggressive the disease is and how sensitive...

2011-01-21 09:03:00

BERLIN, January 21, 2011 /PRNewswire-FirstCall/ -- Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five years ago the European Medicines Agency EMA approved this drug for the first time and as a result of the current renewal process the drug has now been granted an indefinite approval....

2011-01-20 13:30:00

BOSTON, Jan. 20, 2011 /PRNewswire-USNewswire/ -- Through a grant provided by the Caring for Carcinoid Foundation (www.caringforcarcinoid.org), researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center have discovered several key mutations in pancreatic neuroendocrine tumors. This significant finding holds the promise of improving patient diagnosis and treatment and brings the neuroendocrine cancer community closer to a cure. Neuroendocrine cancers affect approximately...

8feb3712c100751159257fc0aa2f2bfe1
2011-01-20 15:55:00

John Hopkins University researchers said on Thursday that they have discovered the reason some people are able live for years with the same kind of rare pancreatic cancer that has inflicted people like Apple's CEO Steve Jobs. The team at the university reported in the journal Science Express that patients with certain coding "mistakes" live twice as long as those whose tumors carried other mutations. "One of the most significant things we learned is that each patient with this kind of rare...

2010-12-02 05:00:00

NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved SUTENT® (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with SUTENT as initial treatment is limited in this disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.(1,2)...

2010-11-02 15:30:00

COLUMBIA, Md., Nov. 2, 2010 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA). This maximum grant amount for a single program was awarded to Celsion for its Thermodox® clinical development program, which is currently conducting clinical trials for primary liver cancer and...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related